Lexaria Bioscience (LEXX) has released an update. Lexaria Bioscience is advancing its DehydraTECH drug delivery platform to compete in the booming GLP-1 market, which is dominated by Novo Nordisk’s ...
Lexaria Bioscience (LEXX) has released an update. Lexaria Bioscience has received ethics board approval for its 12-week Phase 1b GLP-1 study, which focuses on diabetes and weight loss, marking a ...
KELOWNA, BC / ACCESS Newswire / April 23, 2025 / Lexaria Bioscience Corp.(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the following ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results